Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: A randomised, multicentre trial

International Journal of Clinical Practice

Volumn 65, Issue 9, 2011, Pages 997-1004

  Lee, Y S ^a   Choo, M S ^b   Lee, J Y ^c   Oh, S J ^d   Lee, K S ^e  

^a Sungkyunkwan University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Seoul National University Hospital   (South Korea)

^e Samsung Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

TOLTERODINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; OVERACTIVE BLADDER; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RETREATMENT; RISK FACTOR; UNIVERSITY HOSPITAL; URINARY FREQUENCY; URINARY URGENCY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; REFERRAL AND CONSULTATION; RETREATMENT; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINATION; YOUNG ADULT;

EID: 80051885471     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02728.x     Document Type: Article

References (30)

1. Abrams P, Cardozo L, Fall M, et al., The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78. (Pubitemid 34195211)
2. Irwin DE, Milsom I, Hunskaar S, et al., Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-14; discussion 14-5.
3. Lee YS, Lee KS, Jung JH, et al., Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study. World J Urol 2011; 29: 185-90.
4. Lee KS, Lee YS,. Overactive Bladder. Korean J Urol 2007; 48: 1191-208.
5. Stewart WF, Van Rooyen JB, Cundiff GW, et al., Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36. (Pubitemid 44175300)
6. Liberman JN, Hunt TL, Stewart WF, et al., Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 2001; 57: 1044-50. (Pubitemid 32455563)
7. Kobelt G,. Economic considerations and outcome measurement in urge incontinence. Urology 1997; 50 (6A Suppl.): 100-7; discussion 8-10. (Pubitemid 28027845)
8. Steers WD, Lee KS,. Depression and incontinence. World J Urol 2001; 19: 351-7. (Pubitemid 33777081)
9. Coyne KS, Tubaro A, Brubaker L, Bavendam T,. Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. Urology 2006; 68 (2 Suppl.): 9-16. (Pubitemid 44189488)
10. Pleil AM, Coyne KS, Reese PR, et al., The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue-the BSW. Value Health 2005; 8 (Suppl. 1): S25-34. (Pubitemid 43110283)
11. Coyne K, Revicki D, Hunt T, et al., Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002; 11: 563-74. (Pubitemid 34876130)
12. Coyne KS, Matza LS, Kopp Z, Abrams P,. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006; 49: 1079-86. (Pubitemid 43673993)
13. Cardozo L, Coyne KS, Versi E,. Validation of the urgency perception scale. BJU Int 2005; 95: 591-6. (Pubitemid 40311479)
14. Rogers RG, Omotosho T, Bachmann G, et al., Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 months. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20: 381-5.
15. Rogers R, Bachmann G, Jumadilova Z, et al., Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19: 1551-7.
16. Chapple CR, Martinez-Garcia R, Selvaggi L, et al., A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48: 464-70. (Pubitemid 41188406)
17. Sand PK, Morrow JD, Bavendam T, et al., Efficacy and tolerability of fesoterodine in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20: 827-35.
18. Choo MS, Song C, Kim JH, et al., Changes in overactive bladder symptoms after discontinuation of successful 3-month treatment with an antimuscarinic agent: a prospective trial. J Urol 2005; 174: 201-4. (Pubitemid 40825714)
19. Noe L, Sneeringer R, Patel B, Williamson T,. The implications of poor medication persistence with treatment for overactive bladder. Manag Care Interface 2004; 17: 54-60. (Pubitemid 40444166)
20. Krueger KP, Berger BA, Felkey B,. Medication adherence and persistence: a comprehensive review. Adv Ther 2005; 22: 313-56. (Pubitemid 43003324)
21. Shaya FT, Blume S, Gu A, et al., Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 2005; 11 (4 Suppl.): S121-9. (Pubitemid 41022720)
22. D'Souza AO, Smith MJ, Miller LA, et al., Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm 2008; 14: 291-301. (Pubitemid 351711980)
23. Wyman JF, Fantl JA, McClish DK, Bump RC,. Comparative efficacy of behavioral interventions in the management of female urinary incontinence. Continence Program for Women Research Group. Am J Obstet Gynecol 1998; 179: 999-1007. (Pubitemid 28489298)
24. Burgio KL, Locher JL, Goode PS, et al., Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 1998; 280: 1995-2000.
25. Klutke CG, Burgio KL, Wyman JF, et al., Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication. J Urol 2009; 181: 2599-607.
26. Mattiasson A, Blaakaer J, Hoye K, Wein AJ,. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. BJU Int 2003; 91: 54-60.
27. Burgio KL, Kraus SR, Menefee S, et al., Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial. Ann Intern Med 2008; 149: 161-9.
28. Liu HT, Kuo HC,. Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J Urol 2008; 179: 2270-4.
29. Kim JC, Park EY, Seo SI, et al., Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol 2006; 175: 1773-6; discussion 6.
30. Liu HT, Chancellor MB, Kuo HC,. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int 2009; 103: 1668-72.